Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2025British Journal of HaematologyOpen Access

CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia

View Full Paper
Ask AI
Bookmark
Share

Authors

ADAlexandra DreyzinNHNoa G. HoltzmanCBChallice L. Bonifant

Discussion

Loading...

Member takes

Overview

Review assesses clinical outcomes of CD123-targeting therapies in AML, indicating challenges in efficacy and toxicity.

Key Points

  • MAIN FINDING: CD123-targeting immunotherapies show variable anti-tumor responses in acute myeloid leukaemia (AML).
  • KEY EVIDENCE: Clinical outcomes of monoclonal antibodies, CAR T cells, and other therapies were reviewed, revealing mixed results.
  • APPROACH: The review discusses various targeting strategies and preclinical developments aimed at improving treatment outcomes for AML.
  • SIGNIFICANCE: Understanding challenges in therapy efficacy and toxicity can inform future clinical strategies for AML treatment.

Cite This Study

Dreyzin et al. (2025) studied this question.

synapsesocial.com/papers/689a0933e6551bb0af8ce580https://doi.org/10.1111/bjh.70019
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1T-Cell Engagers in Acute Myeloid Leukemia: Molecular Targets, Structure, and Therapeutic Challenges2025
  2. 2Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia2025 · 3 citations
  3. 3CAR‐DC combined with CAR‐T therapy for relapsed/refractory acute myeloid leukaemia: Research progress and future perspectives2025 · 3 citations
  4. 4The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS2025 · 10 citations
  5. 5A novel B7-H3-specific binder enables effective CAR T-cell therapy in an Acute Myeloid Leukemia experimental model2025